Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 13 entries
Sorted by: Best Match Show Resources per page
Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Charokopou M, Vioix H, Verheggen BG, Dillon S, Franks D.
PMID: 27200640
Value Health. 2014 Nov;17(7):A343. doi: 10.1016/j.jval.2014.08.690. Epub 2014 Oct 26.

No abstract available.

Cite
Charokopou M, Vioix H, Verheggen BG, et al. Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective. Value Health. 2014;17(7):A343doi: 10.1016/j.jval.2014.08.690.
Charokopou, M., Vioix, H., Verheggen, B. G., Dillon, S., & Franks, D. (2014). Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A343. https://doi.org/10.1016/j.jval.2014.08.690
Charokopou, M, et al. "Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A343. doi: https://doi.org/10.1016/j.jval.2014.08.690
Charokopou M, Vioix H, Verheggen BG, Dillon S, Franks D. Dapagliflozin (Forxiga®) Versus Glipizide As Add-On Therapies In Type 2 Diabetes Mellitus (T2dm); An Update of The Cost-Effectiveness Based On Long-Term Clinical Evidence From Uk Nhs Perspective. Value Health. 2014 Nov;17(7):A343. doi: 10.1016/j.jval.2014.08.690. Epub 2014 Oct 26. PMID: 27200640.
Copy Download .nbib Format: NLM
Construction of high-quality NN potential models.

Physical review. C, Nuclear physics

de Swart JJ, Klomp RA, Stoks VG, Terheggen CP.
PMID: 9969572
Phys Rev C Nucl Phys. 1994 Jun;49(6):2950-2962. doi: 10.1103/physrevc.49.2950.

No abstract available.

Cite
de Swart JJ, Klomp RA, Stoks VG, et al. Construction of high-quality NN potential models. Phys Rev C Nucl Phys. 1994;49(6):2950-2962doi: 10.1103/physrevc.49.2950.
de Swart JJ, Klomp, R. A., Stoks, V. G., & Terheggen, C. P. (1994). Construction of high-quality NN potential models. Physical review. C, Nuclear physics, 49(6), 2950-2962. https://doi.org/10.1103/physrevc.49.2950
de Swart JJ, et al. "Construction of high-quality NN potential models." Physical review. C, Nuclear physics vol. 49,6 (1994): 2950-2962. doi: https://doi.org/10.1103/physrevc.49.2950
de Swart JJ, Klomp RA, Stoks VG, Terheggen CP. Construction of high-quality NN potential models. Phys Rev C Nucl Phys. 1994 Jun;49(6):2950-2962. doi: 10.1103/physrevc.49.2950. PMID: 9969572.
Copy Download .nbib Format: NLM
A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens.

BMC medicine

Drew DR, Wilson DW, Elliott SR, Cross N, Terheggen U, Hodder AN, Siba PM, Chelimo K, Dent AE, Kazura JW, Mueller I, Beeson JG.
PMID: 27658419
BMC Med. 2016 Sep 23;14(1):144. doi: 10.1186/s12916-016-0691-6.

BACKGROUND: The polymorphic nature of many malaria vaccine candidates presents major challenges to achieving highly efficacious vaccines. Presently, there is very little knowledge on the prevalence and patterns of functional immune responses to polymorphic vaccine candidates in populations to...

Cite
Drew DR, Wilson DW, Elliott SR, et al. A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens. BMC Med. 2016;14(1):144doi: 10.1186/s12916-016-0691-6.
Drew, D. R., Wilson, D. W., Elliott, S. R., Cross, N., Terheggen, U., Hodder, A. N., Siba, P. M., Chelimo, K., Dent, A. E., Kazura, J. W., Mueller, I., & Beeson, J. G. (2016). A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens. BMC medicine, 14(1), 144. https://doi.org/10.1186/s12916-016-0691-6
Drew, Damien R, et al. "A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens." BMC medicine vol. 14,1 (2016): 144. doi: https://doi.org/10.1186/s12916-016-0691-6
Drew DR, Wilson DW, Elliott SR, Cross N, Terheggen U, Hodder AN, Siba PM, Chelimo K, Dent AE, Kazura JW, Mueller I, Beeson JG. A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens. BMC Med. 2016 Sep 23;14(1):144. doi: 10.1186/s12916-016-0691-6. PMID: 27658419; PMCID: PMC5034621.
Copy Download .nbib Format: NLM
Diagnosis and Treatment of Sciatica in the Netherlands: A Survey among Neurologists and Anesthesiologists.

European neurology

Ter Meulen B, Overweg C, Feenstra T, Brouwer B, Terheggen M, van Dongen H, Kallewaard JW, Ostelo R, Weinstein H.
PMID: 33902042
Eur Neurol. 2021;84(4):219-229. doi: 10.1159/000515578. Epub 2021 Apr 26.

BACKGROUND: This study aimed to assess how Dutch neurologists and anesthesiologists diagnose and treat people with sciatica in secondary care and to evaluate their adherence to the newest guidelines.METHODS: We conducted a cross-sectional survey. Respondents were asked about their...

Cite
Ter Meulen B, Overweg C, Feenstra T, et al. Diagnosis and Treatment of Sciatica in the Netherlands: A Survey among Neurologists and Anesthesiologists. Eur Neurol. 2021;84(4):219-229doi: 10.1159/000515578.
Ter Meulen, B., Overweg, C., Feenstra, T., Brouwer, B., Terheggen, M., van Dongen, H., Kallewaard, J. W., Ostelo, R., & Weinstein, H. (2021). Diagnosis and Treatment of Sciatica in the Netherlands: A Survey among Neurologists and Anesthesiologists. European neurology, 84(4), 219-229. https://doi.org/10.1159/000515578
Ter Meulen, Bastiaan, et al. "Diagnosis and Treatment of Sciatica in the Netherlands: A Survey among Neurologists and Anesthesiologists." European neurology vol. 84,4 (2021): 219-229. doi: https://doi.org/10.1159/000515578
Ter Meulen B, Overweg C, Feenstra T, Brouwer B, Terheggen M, van Dongen H, Kallewaard JW, Ostelo R, Weinstein H. Diagnosis and Treatment of Sciatica in the Netherlands: A Survey among Neurologists and Anesthesiologists. Eur Neurol. 2021;84(4):219-229. doi: 10.1159/000515578. Epub 2021 Apr 26. PMID: 33902042.
Copy Download .nbib Format: NLM
The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Charokopou M, Vioix H, Verheggen BG, Bratt T, Franks D.
PMID: 27200638
Value Health. 2014 Nov;17(7):A343. doi: 10.1016/j.jval.2014.08.689. Epub 2014 Oct 26.

No abstract available.

Cite
Charokopou M, Vioix H, Verheggen BG, et al. The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective. Value Health. 2014;17(7):A343doi: 10.1016/j.jval.2014.08.689.
Charokopou, M., Vioix, H., Verheggen, B. G., Bratt, T., & Franks, D. (2014). The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A343. https://doi.org/10.1016/j.jval.2014.08.689
Charokopou, M, et al. "The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A343. doi: https://doi.org/10.1016/j.jval.2014.08.689
Charokopou M, Vioix H, Verheggen BG, Bratt T, Franks D. The Impact of Long-Term Clinical Evidence on Cost-Effectiveness of Exenatide Once Weekly (Bydureon®) Versus Insulin Glargine for Patients With Type 2 Diabetes Mellitus (T2dm) From A Uk Nhs Perspective. Value Health. 2014 Nov;17(7):A343. doi: 10.1016/j.jval.2014.08.689. Epub 2014 Oct 26. PMID: 27200638.
Copy Download .nbib Format: NLM
Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin.

ClinicoEconomics and outcomes research : CEOR

Stephens JM, Gao X, Patel DA, Verheggen BG, Shelbaya A, Haider S.
PMID: 24068869
Clinicoecon Outcomes Res. 2013 Sep 16;5:447-57. doi: 10.2147/CEOR.S46991. eCollection 2013.

BACKGROUND: Previous economic analyses evaluating treatment of methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft-tissue infections (cSSTI) failed to include all direct treatment costs such as outpatient parenteral antibiotic therapy (OPAT). Our objective was to develop an economic model...

Cite
Stephens JM, Gao X, Patel DA, et al. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clinicoecon Outcomes Res. 2013;5:447-57doi: 10.2147/CEOR.S46991.
Stephens, J. M., Gao, X., Patel, D. A., Verheggen, B. G., Shelbaya, A., & Haider, S. (2013). Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. ClinicoEconomics and outcomes research : CEOR, 5447-57. https://doi.org/10.2147/CEOR.S46991
Stephens, Jennifer M, et al. "Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin." ClinicoEconomics and outcomes research : CEOR vol. 5 (2013): 447-57. doi: https://doi.org/10.2147/CEOR.S46991
Stephens JM, Gao X, Patel DA, Verheggen BG, Shelbaya A, Haider S. Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin. Clinicoecon Outcomes Res. 2013 Sep 16;5:447-57. doi: 10.2147/CEOR.S46991. eCollection 2013. PMID: 24068869; PMCID: PMC3782516.
Copy Download .nbib Format: NLM
Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Charokopou M, Vioix H, Verheggen BG, Maddocks D, Bratt T, Franks D.
PMID: 27200644
Value Health. 2014 Nov;17(7):A344-5. doi: 10.1016/j.jval.2014.08.696. Epub 2014 Oct 26.

No abstract available.

Cite
Charokopou M, Vioix H, Verheggen BG, et al. Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective. Value Health. 2014;17(7):A344-5doi: 10.1016/j.jval.2014.08.696.
Charokopou, M., Vioix, H., Verheggen, B. G., Maddocks, D., Bratt, T., & Franks, D. (2014). Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A344-5. https://doi.org/10.1016/j.jval.2014.08.696
Charokopou, M, et al. "Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A344-5. doi: https://doi.org/10.1016/j.jval.2014.08.696
Charokopou M, Vioix H, Verheggen BG, Maddocks D, Bratt T, Franks D. Economic Assessment of Delaying Insulin Treatment Through The Use of Newer Anti-Diabetic Agents, Dapagliflozin (Forxiga®) And Exenatide (Bydureon®), Both As Add-On To Metformin; A Cost-Effectiveness Analysis From A Uk Nhs Perspective. Value Health. 2014 Nov;17(7):A344-5. doi: 10.1016/j.jval.2014.08.696. Epub 2014 Oct 26. PMID: 27200644.
Copy Download .nbib Format: NLM
Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Charokopou M, Vioix H, Eddowes LA, Griffiths M, Verheggen BG, Gabriel Z, Tolley K.
PMID: 27200660
Value Health. 2014 Nov;17(7):A347. doi: 10.1016/j.jval.2014.08.710. Epub 2014 Oct 26.

No abstract available.

Cite
Charokopou M, Vioix H, Eddowes LA, et al. Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective. Value Health. 2014;17(7):A347doi: 10.1016/j.jval.2014.08.710.
Charokopou, M., Vioix, H., Eddowes, L. A., Griffiths, M., Verheggen, B. G., Gabriel, Z., & Tolley, K. (2014). Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A347. https://doi.org/10.1016/j.jval.2014.08.710
Charokopou, M, et al. "Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A347. doi: https://doi.org/10.1016/j.jval.2014.08.710
Charokopou M, Vioix H, Eddowes LA, Griffiths M, Verheggen BG, Gabriel Z, Tolley K. Cost-Effectiveness of Dapagliflozin Compared To Dpp-4 Inhibitors as Triple Therapy In Combination With Metformin and A Sulphonylurea In The Treatment Of Type 2 Diabetes Mellitus From A Uk Health Care Perspective. Value Health. 2014 Nov;17(7):A347. doi: 10.1016/j.jval.2014.08.710. Epub 2014 Oct 26. PMID: 27200660.
Copy Download .nbib Format: NLM
Comparative Cost-Effectiveness Analysis of Adding Twice-Daily Exenatide To Insulin Glargine Versus Adding Insulin Lispro To Treat Type 2 Diabetes In Spain.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Sánchez-Covisa J, Capel M, Baeten S, Verheggen BG.
PMID: 27200673
Value Health. 2014 Nov;17(7):A349-50. doi: 10.1016/j.jval.2014.08.723. Epub 2014 Oct 26.

No abstract available.

Cite
Sánchez-Covisa J, Capel M, Baeten S, et al. Comparative Cost-Effectiveness Analysis of Adding Twice-Daily Exenatide To Insulin Glargine Versus Adding Insulin Lispro To Treat Type 2 Diabetes In Spain. Value Health. 2014;17(7):A349-50doi: 10.1016/j.jval.2014.08.723.
Sánchez-Covisa, J., Capel, M., Baeten, S., & Verheggen, B. G. (2014). Comparative Cost-Effectiveness Analysis of Adding Twice-Daily Exenatide To Insulin Glargine Versus Adding Insulin Lispro To Treat Type 2 Diabetes In Spain. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A349-50. https://doi.org/10.1016/j.jval.2014.08.723
Sánchez-Covisa, J, et al. "Comparative Cost-Effectiveness Analysis of Adding Twice-Daily Exenatide To Insulin Glargine Versus Adding Insulin Lispro To Treat Type 2 Diabetes In Spain." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A349-50. doi: https://doi.org/10.1016/j.jval.2014.08.723
Sánchez-Covisa J, Capel M, Baeten S, Verheggen BG. Comparative Cost-Effectiveness Analysis of Adding Twice-Daily Exenatide To Insulin Glargine Versus Adding Insulin Lispro To Treat Type 2 Diabetes In Spain. Value Health. 2014 Nov;17(7):A349-50. doi: 10.1016/j.jval.2014.08.723. Epub 2014 Oct 26. PMID: 27200673.
Copy Download .nbib Format: NLM
The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Sánchez-Covisa J, Capel M, Schmidt R, Charokopou M, Verheggen BG.
PMID: 27200677
Value Health. 2014 Nov;17(7):A350. doi: 10.1016/j.jval.2014.08.727. Epub 2014 Oct 26.

No abstract available.

Cite
Sánchez-Covisa J, Capel M, Schmidt R, et al. The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain. Value Health. 2014;17(7):A350doi: 10.1016/j.jval.2014.08.727.
Sánchez-Covisa, J., Capel, M., Schmidt, R., Charokopou, M., & Verheggen, B. G. (2014). The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A350. https://doi.org/10.1016/j.jval.2014.08.727
Sánchez-Covisa, J, et al. "The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A350. doi: https://doi.org/10.1016/j.jval.2014.08.727
Sánchez-Covisa J, Capel M, Schmidt R, Charokopou M, Verheggen BG. The Cost-Effectiveness of Dapagliflozin In Combination With Insulin for the Treatment of Type 2 Diabetes Mellitus (T2dm) In Spain. Value Health. 2014 Nov;17(7):A350. doi: 10.1016/j.jval.2014.08.727. Epub 2014 Oct 26. PMID: 27200677.
Copy Download .nbib Format: NLM
Impact of Empowering Leadership on Antimicrobial Stewardship: A Single Center Study in a Neonatal and Pediatric Intensive Care Unit and a Literature Review.

Frontiers in pediatrics

Steinmann KE, Lehnick D, Buettcher M, Schwendener-Scholl K, Daetwyler K, Fontana M, Morgillo D, Ganassi K, O'Neill K, Genet P, Burth S, Savoia P, Terheggen U, Berger C, Stocker M.
PMID: 30370263
Front Pediatr. 2018 Oct 12;6:294. doi: 10.3389/fped.2018.00294. eCollection 2018.

No abstract available.

Cite
Steinmann KE, Lehnick D, Buettcher M, et al. Impact of Empowering Leadership on Antimicrobial Stewardship: A Single Center Study in a Neonatal and Pediatric Intensive Care Unit and a Literature Review. Front Pediatr. 2018;6:294doi: 10.3389/fped.2018.00294.
Steinmann, K. E., Lehnick, D., Buettcher, M., Schwendener-Scholl, K., Daetwyler, K., Fontana, M., Morgillo, D., Ganassi, K., O'Neill, K., Genet, P., Burth, S., Savoia, P., Terheggen, U., Berger, C., & Stocker, M. (2018). Impact of Empowering Leadership on Antimicrobial Stewardship: A Single Center Study in a Neonatal and Pediatric Intensive Care Unit and a Literature Review. Frontiers in pediatrics, 6294. https://doi.org/10.3389/fped.2018.00294
Steinmann, Karin E, et al. "Impact of Empowering Leadership on Antimicrobial Stewardship: A Single Center Study in a Neonatal and Pediatric Intensive Care Unit and a Literature Review." Frontiers in pediatrics vol. 6 (2018): 294. doi: https://doi.org/10.3389/fped.2018.00294
Steinmann KE, Lehnick D, Buettcher M, Schwendener-Scholl K, Daetwyler K, Fontana M, Morgillo D, Ganassi K, O'Neill K, Genet P, Burth S, Savoia P, Terheggen U, Berger C, Stocker M. Impact of Empowering Leadership on Antimicrobial Stewardship: A Single Center Study in a Neonatal and Pediatric Intensive Care Unit and a Literature Review. Front Pediatr. 2018 Oct 12;6:294. doi: 10.3389/fped.2018.00294. eCollection 2018. PMID: 30370263; PMCID: PMC6194187.
Copy Download .nbib Format: NLM
Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany.

Clinical and translational allergy

Verheggen BG, Westerhout KY, Schreder CH, Augustin M.
PMID: 25691953
Clin Transl Allergy. 2015 Jan 21;5:1. doi: 10.1186/s13601-015-0045-z. eCollection 2015.

BACKGROUND: Allergoids are chemically modified allergen extracts administered to reduce allergenicity and to maintain immunogenicity. Oralair® (the 5-grass tablet) is a sublingual native grass allergen tablet for pre- and co-seasonal treatment. Based on a literature review, meta-analysis, and cost-effectiveness...

Cite
Verheggen BG, Westerhout KY, Schreder CH, et al. Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. Clin Transl Allergy. 2015;5:1doi: 10.1186/s13601-015-0045-z.
Verheggen, B. G., Westerhout, K. Y., Schreder, C. H., & Augustin, M. (2015). Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. Clinical and translational allergy, 51. https://doi.org/10.1186/s13601-015-0045-z
Verheggen, Bram G, et al. "Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany." Clinical and translational allergy vol. 5 (2015): 1. doi: https://doi.org/10.1186/s13601-015-0045-z
Verheggen BG, Westerhout KY, Schreder CH, Augustin M. Health economic comparison of SLIT allergen and SCIT allergoid immunotherapy in patients with seasonal grass-allergic rhinoconjunctivitis in Germany. Clin Transl Allergy. 2015 Jan 21;5:1. doi: 10.1186/s13601-015-0045-z. eCollection 2015. PMID: 25691953; PMCID: PMC4330981.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 13 entries